AdAlta Ltd
1AD
Company Profile
Business description
AdAlta Ltd is engaged in drug discovery and developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The principal business of AdAlta is the discovery and development of next-generation protein and cell-based therapeutics. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis and CAR-T cancer therapeutics.
Contact
Science Drive
La Trobe Institute for Molecular Science, Room 204, LIMS2
La Trobe University
BundooraVIC3086
AUST: +61 394795159
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
12
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,579.50 | 49.70 | 0.58% |
| CAC 40 | 7,853.47 | 16.68 | 0.21% |
| DAX 40 | 23,695.59 | 168.58 | 0.72% |
| Dow JONES (US) | 42,322.75 | 271.69 | 0.65% |
| FTSE 100 | 8,633.75 | 48.74 | 0.57% |
| HKSE | 23,278.09 | 175.07 | -0.75% |
| NASDAQ | 19,112.32 | 34.49 | -0.18% |
| Nikkei 225 | 37,659.39 | 96.12 | -0.25% |
| NZX 50 Index | 12,813.83 | 66.99 | -0.52% |
| S&P 500 | 5,916.93 | 24.35 | 0.41% |
| S&P/ASX 200 | 8,345.30 | 47.80 | 0.58% |
| SSE Composite Index | 3,361.22 | 19.60 | -0.58% |